Consistent terminology for medication-related problems in pharmacogenomic cases

Thomas M. Polasek; Sam Mostafa; Carl M.J. Kirkpatrick

doi:10.1503/jpn.230022-l

Article Information

vol. 48 no. 3 E151-E152

DOI

https://doi.org/10.1503/jpn.230022-l

History

Published online May 12, 2023.

© 2023 CMA Impact Inc. or its licensors This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

Author Information

Thomas M. Polasek, BPahrm, PhD,
Sam Mostafa, BPharm,
Carl M.J. Kirkpatrick, BPharm, PhD

From Certara, Princeton, New Jersey, USA (Polasek); the Centre for Medicines Use and Safety, Monash University, Melbourne, Victoria, Australia (Polasek, Mostafa, Kirkpatrick); and myDNA Life, Australia Limited, South Yarra, Victoria, Australia (Mostafa)